Novartis licenses Factor XI Ab to Blackstone-backed $250m bio firm - BioProcess Insider

Novartis licenses Factor XI Ab to Blackstone-backed $250m bio firm  BioProcess Insider

Newly launched firm Anthos Therapeutics has licensed Novartis candidate MAA868 and will look to develop it for cardiovascular disorders. Novartis retains a ...